Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 287 | Longs Won 134/287 46% | Profit Factor 1.04 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $3,580.29 |
| Average Win $1,700.86 | Best Trade (Nov 23) $32,086.94 | Sharpe Ratio -55.67 |
| Average Loss -$1,435.36 | Worst Trade (Jul 07) -$18,124.58 | Z-Score -2.3 (100%) |
| Commissions $0 | Avg. Trade Length 2m 1w 1d | Expectancy $29.23 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | 32.61% | 45.69% | 55.66% | 64.02% | 71.37% | 77.99% | 84.06% | 89.71% | 95% |
| Consecutive Losing Trades | 76 | 68 | 60 | 53 | 45 | 38 | 30 | 23 | 15 | 8 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
TARS Tarsus Pharmaceuticals Inc. | 1,556.29 | $108,963.76 | $108,387.94 | - | -$575.82 | -0.53% | +2.119% |